Abstract
Introduction: In India, Aspirin is marketed as multiple preparations for antiplatelet use and its drug release pattern is likely to affect efficacy.
Objectives: The study compares anti-platelet efficacy of four preparations of aspirin against ADP-induced platelet aggregability and bleeding time (BT); and assesses correlation between steady state plasma concentration (CSS) and antiplatelet effect of daily 150mg Aspirin.
Methods: This was a four armed, randomised, investigator-blinded, parallel-group, comparative study. Study was conducted in 121 subjects of Type 2 DM on oral anti-diabetics having one or more cardiovascular risk factors. Each subject was randomized to receive Plain aspirin, soluble, effervescent or enteric coated, for 15 days. Blood samples were taken at day 0 and day 15, two hours after dosing.
Results: Total 121 subjects completed study (Plain 30, soluble 31, effervescent 30 and enteric coated 30) and the baseline characteristics were similar among all groups. All preparations inhibited platelet aggregation (Reduction from day 0 to day 15: plain-25.9%, soluble-23.9%, effervescent-23.5%, enteric coated-26.4%; p=0.89) and increased BT (Rise: plain-236.4%, soluble-236.1%, effervescent-229%, enteric coated-256.7%; p=0.87) to a similar extent. Salicylate CSS measured at day 15 was significantly higher in effervescent (23.75mg/L) as compared to enteric coated (19.73mg/L) and soluble (19.27mg/L). Plain aspirin produced salicylate CSS of 20.8mg/L. There was no significant correlation between salicylate CSS and anti-platelet activity for study population [r= -0.124, p= 0.179] or for individual groups.
Conclusions: -All preparations produced comparable antiplatelet effect which did not correlate with steady state plasma salicylate concentration at daily dose of 150mg.
Keywords: Aspirin, Diabetes, Antiplatelet effect, Serum salicylate.
References
- Farrugia CA. The antiplatelet activity of aspirin. The chronic ill. 1999;3:14-18
URL:http://www.mcppnet.org/publications/ISSUE03-5.pdf Accessed on: October 6, 2016 9:01:37 PM Executive Summary. In: International Diabetes Federation, 7 ed. Brussels, Belgium: International Diabetes Federation, 2015 p.12-20
URL:http://www.diabetesatlas.org Accessed on: February 03 2016, 1:29:13PM
- Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013;368:1613–1624
URL:http://globalhealth.emory.edu/resources/scholarly_publications/pdfs/2013_achievementofgoals_NEJM.pdf Accessed on: October 6, 2016 9:11:27 PM
- Carr ME. Diabetes mellitus: A hypercoaguable state. J diabetes Complications 2001;15:44-54.
URL:https://www.ncbi.nlm.nih.gov/pubmed/11259926 Accessed on: October 6, 2016 9:12:21 PM
- American Diabetes Association. Cardiova-scular Disease and Risk Management. Diabetes Care 2016;39(Suppl. 1):S60–S71
- URL:http://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement_1.DC2/2016-Standards-of-Care.pdf Accessed on:February 03, 2016, 1:43:13 PM
- Clarke R. J., Mayo G., Price P., FitzGerald G. A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325(16):1137–1141.
URL:http://www.nejm.org/doi/full/10.1056/NEJM199110173251605#t=article Accessed on: October 6, 2016 8:12:23 PM.
- De BerardisG,Michele S, Giovanni S F M, Fabio P, Giusi G, Gianni Tet al Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:4531.
- Whitley E, Ball J Statistics review 4: sample size calculations. Crit Care. 2002;6(4):335-41.
- Mendis S, Puska P, Norrving B editors. Cardiovascular disease (CVD) Backgrounder – Epresspack- Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization (in collaboration with the World Heart Federation and World Stroke Organization), Geneva 2011.
- O’Brien J R. Platelet aggregation. II. Some results from a new method of study. J ClinPathol. 1962;15:452-481.
- 0' Brien JR. A comparison of platelet aggregation produced by seven compounds and comparison of their inhibitors. J Clinical Path 1964;17:275-281.
- Pal GK, Pal P. Textbook of Practical Physiology, 3rd edn. 2010. p.100–01
- Rapid determination of salicylates in biological fluids: Biochemical J. 1954; 54; 301.
- Khan F., Li M., Schlindwein W. Comparison of In Vitro Dissolution Tests for Commercially Available Aspirin Tablets. Dissolution Technologies 2013;20(1):48-58
- Appendix 7: Disintegration and Dissolution Tests. Indian Pharmacopoeia. 1996 Vol II. Delhi: The Controller of Publications; 1996. p. 734-46, A-80-84.
- Opadry Enteric -94 Series, Preparation and Use Guidelines. Colorcon Technical Liter-ature. Ads_Opadry Enteric _ Aspirin_V1_12.2009
URL:https://www.colorcon.com/literature/marketing/mr/Delayed%20Release/Opadry%20Enteric/Chinese/ads_opadry%20enteric_aspirin_FINAL_02.09.10.pdf Accessed on 8th August 2016; 04:32:12 pm
- Gatti G, Barzaghi N, AttardoParrinello G, Vitiello B, Perucca E. Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. Int J ClinPharmacol Res. 1989;9(6):385-9.
- Cox D, Maree AO, Dooley M, Conroy R, Byrne MF and Fitzgerald DJ. Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers. Stroke 2006;37:2153-2158.
- Van Hecken A, Juliano ML, Depre´ M , De LepeleireI, Arnout J, Dynder A et al. Effects of enteric-coated, low-dose aspirin on parameters of platelet function. Aliment PharmacolTher 2002; 16: 1683–1688.
- Cruz, J. P. De, Guerrero A., Gonza, J. A. Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans, 131568. European Journal of Clinical Pharmacology.2002; 11(57): 775–780.
Corresponding Author
Bharti Ramchand Daswani
Contact No. +91-9421965337, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v5i7.208
